

FORM PTO-1449

Att. Docket No.: REG 334-A-US

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

USSN : 10/009,620

Applicant: Wiegand, S. J.

Date Filed: December 11, 2001

Title: Methods of Imaging and Targeting
Tumor Vasculature

Examiner: Not yet known

Group Art Unit: 3736

February 6, 2003

RECEIVED

FEB 20 2003

U.S. PATENT DOCUMENTS

TECHNOLOGY CENTER R3700

<u>Examiner Initials</u>	<u>Patent Number</u>	<u>Issue Date</u>	<u>Publication Number</u>	<u>Publication Date</u>	<u>Name</u>
------------------------------	--------------------------	-----------------------	-------------------------------	-----------------------------	-------------

FOREIGN PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Document Number</u>	<u>Date</u>	<u>Country</u>	<u>Class/ Date Subclass</u>	<u>Translation Yes No</u>
<u>120</u>	WO/99 40947	08/19/99	PCT		
<u>120</u>	WO/00 18439	04/06/00	PCT		

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, etc.)

120 Maisonpierre, PC, et al., 1997, "Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis", Science 277:55-60

— Kirsch, JE, 1991, "Basic principles of magnetic resonance contrast agents", Top Magn Reson Imaging 3:1-18

— Wallis, F. and Gilbert, FJ, 1999, J R, "Magnetic resonance imaging in oncology: an overview", Coll Surg Edinb 44:117-125

— Schiepers, C. and Hoh, CK, 1998, "Positron emission tomography as a diagnostic tool in oncology", Eur Radiol 8:1481-1494

✓ Ferrand, SK, et al., 1999, "What is new in nuclear medicine imaging?", Surg Oncol Clin N Am 8:185-204

- KCI Asahara, T. et al., 1998, "Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization", Circ Res 83(3):233-240.
- Lin, P., et al., 1998, "Anti-angiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2", PNAS USA 95:8829-8834.
- Tanaka, S., et al., 1999, "Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma", J Clin Invest 103(3):341-345.
- Molema, G., et al., 2000, "The use of bispecific antibodies in tumor cell and tumor vasculature directed immunotherapy", J Control Release 64 (1-3):229-239.
- Berns, A., 1999, "Mouse model for cancer at center stage - AACR special meeting: Cancer biology and the mutant mouse: New methods, new models, new insights, Keystone, Colorado, USA 31 January - 5 February 1999", Trends in Genetics 15(5):177.
- Lauren, J., et al., 1998, "Is angiopoietin-2 necessary for the initiation of angiogenesis?", Am J Path 153(5):1333-1339.
- Stratmann, A., et al., 1998, "Cell type-specific expression of angiopoietin-2 suggests a role in glioblastoma angiogenesis", Am J Path 153(5):1459-1466.
- Wong, MP., et al., 1999, "Down-regulated angiopoietin-1/tie2 receptor pathway and enhanced expression of vascular endothelial growth factor and angiopoietin-2 in non-small cell lung carcinoma", Proc Am Assoc Canc Res Annual 40:556.
- Ding, H. et al., 1999, "Expression and hypoxic regulation of angiopoietins and its receptors in human astrocytoma cell lines and tumor specimens", Proc Am Assoc Canc Res Annual 40:556.
- Chan, ASY, et al., 1999, "Angiopoietin-2 and VEGF co-express in the accelerated phase of angiogenesis during anaplastic progression of gliomas", Proc Am Assoc Canc Res Annual 40:414.
- Fujikawa, K., et al., 1998, "Expression of angiopoietin-1, angiopoietin-2, tie-1 and tie-2 in breast cancer", Blood 92(10, Suppl 1, Part1-2, page 174A
- Holash, J, et al., 1999, "Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF", Science, 284(5422):1994-1998.
- Zagzag, D, et al., 1999, "In situ expression of angiopoietins in astrocytoma identifies angiopoietin-2 as an early marker of tumor angiogenesis", Exp Neuro 159(2):391-400.
- Yoshida, Y., et al., 1999, "Expression of angiostatic factors in colorectal cancer", Int J Oncol 15(6):1221-1225.

- AC3 Holash, J., et al., 1999, "New model of tumor angiogenesis: Dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF", *Oncogene*, 19(38):5356-5362.
- Ijland, SAJ, et al., 1999, "Expression of angiogenic and immunosuppressive factors by uveal melanoma cell lines", *Melanoma Res* 9(5):445-450.
- ✓ Theis, H., et al., 1999, "Role of VEGF, angiopoietins and their receptors in angiogenesis of renal cell carcinoma", *J Am Soc Neph* 10, Program and Abstract Issue:186A.

EXAMINER
CONSIDERED

DATE

U-ll-077

3/5/06

EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

By: Linda O. Palladino

Linda O. Palladino
Reg. No. 45,636
Agent for Applicants
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400